In triple-negative breast cancer, a novel peptide–drug conjugate exploits enhanced albumin metabolism in PTEN-deficient cells to deliver chemotherapeutic payloads, showing promise against metastatic disease [110]. The gene discussed is PTEN; the disease is triple-negative breast carcinoma.